Apyx Medical CorporationAPYXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -3.00% | -7.95% | -6.39% | +12.10% | +34.75% |
| Gross Profit Growth | +120.68% | -4.77% | +151.97% | +19.31% | -122.45% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +10.31% | +2.59% | +17.56% | +17.56% | +10.33% |
| Weighted Average Shares Diluted Growth | +10.31% | +2.59% | +17.56% | +17.56% | +10.33% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +10.39% | -6.74% | -11.50% | -0.31% | +8.37% |
| Inventory Growth | -23.77% | -21.54% | -12.14% | +1.61% | +13.72% |
| Asset Growth | -18.17% | -14.92% | -11.02% | -5.53% | +3.08% |
| Book Value per Share Growth | -51.75% | -49.41% | -58.17% | -54.95% | -7.26% |
| Debt Growth | +0.68% | +0.75% | +0.97% | +0.94% | +1.49% |
| R&D Expense Growth | -10.50% | -42.45% | -42.13% | -29.86% | -15.49% |
| SG&A Expenses Growth | +26.83% | -29.15% | +27.39% | -11.85% | +1.37% |